Medtronic Announces Commercial Release of Electrophysiology Catheters and Reports Economic Benefits of Spinal Cord Stimulation

Strategic Insights -

Medtronic, Inc. has announced the U.S. commercial release of two electrophysiology catheters, the Medtronic EnCirclr AL Adjustable Loop Mapping Catheter and the Medtronic RF Enhancr II Single-Curve Ablation Catheter, which have received U.S. Food and Drug Administration clearance. These new technologies aim to complement the skills of electrophysiologists in delivering curative therapies of radio frequency ablation. Additionally, a study has found that the costs of innovative treatment are offset by reductions in postimplant costs over 1-3 years, offering economic benefits that pay for the therapy in less than 2.5 years. This challenges health policy decisions that restrict patient access to spinal cord stimulation based on device and implantation costs alone.

Key Takeaways:

  • Medtronic has released two electrophysiology catheters, the EnCirclr AL and the RF Enhancr II, which have received FDA clearance and are designed to aid electrophysiologists in delivering radio frequency ablation therapies.
  • The costs of innovative spinal cord stimulation treatment are offset by reductions in postimplant costs over 1-3 years, offering economic benefits that pay for the therapy in less than 2.5 years.
  • A study suggests that health policy decisions restricting patient access to spinal cord stimulation based on device and implantation costs alone should be reconsidered, taking into account the therapy's overall costs and benefits.
  • The therapy provides documented relief for victims of chronic pain and offers economic benefits beyond the initial cost of the implantable device.
  • The study was conducted by five collaborating researchers from U.S. and European medical centers and was published in the Journal of Pain and Symptom Management.
  • The therapy uses an implantable device similar to a cardiac pacemaker to block pain signals moving up the spinal cord, providing long-term pain relief.

Statistics:

  • The initial cost of the spinal cord stimulation therapy does not represent the overall costs and benefits of the treatment (according to the study).
  • The therapy's costs are offset by reductions in postimplant costs over 1-3 years.
  • The therapy offers economic benefits that pay for itself in less than 2.5 years.
  • The study suggests that the initial cost of the implantable device is not sufficient to justify restricting patient access to spinal cord stimulation.

Sources:

  • NewsRx.com & NewsRx.net
  • Medtronic, Inc.
  • U.S. Food and Drug Administration
  • Journal of Pain and Symptom Management
  • Jeffrey Olgin, MD, chief of cardiac electrophysiology at the University of California, San Francisco, California.